Screener
G&A at other companies
Other financials
Where this comes from
Reported directly by Aurinia Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.
The source filing: Aurinia Pharmaceuticals’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 8:16 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001600620-26-000062
| Line item | Three Months Ended / June 30, 2026 | Three Months Ended / June 30, 2025 | Six Months Ended / June 30, 2026 | Six Months Ended / June 30, 2025 |
|---|---|---|---|---|
| Total revenue | 83,220 | 70,008 | 160,925 | 132,473 |
| Operating expenses | ||||
| Cost of revenue | 6,555 | 7,115 | 13,060 | 15,689 |
| Selling, general and administrative | 23,508 | 26,018 | 45,537 | 46,357 |
| Research and development | 13,050 | 7,432 | 20,520 | 13,175 |
| Restructuring | — | 114 | — | 1,647 |
| Other (income) expense, net | (6,234) | 9,246 | (5,955) | 13,675 |
| Total operating expenses | 36,879 | 49,925 | 73,162 | 90,543 |
Item 1. Financial Statements.
FAQ
- What is Aurinia Pharmaceuticals's G&A?
- Aurinia Pharmaceuticals (AUPH) reported G&A of $23.51M in Q2 2026.
- How has Aurinia Pharmaceuticals's G&A changed year-over-year?
- Aurinia Pharmaceuticals's G&A decreased by 9.6% year-over-year, from $26.02M to $23.51M.
- What is the long-term trend for Aurinia Pharmaceuticals's G&A?
- Over 4 years (2021 to 2025), Aurinia Pharmaceuticals's G&A has grown at a -12.5% compound annual growth rate (CAGR), from $173.54M to $101.79M.
- What does G&A mean?
- Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.
Ask your AI about Aurinia Pharmaceuticals's g&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude